This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About Acorda (ACOR) Rating Upgrade to Buy
by Zacks Equity Research
Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View
by Zacks Equity Research
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Pacira Gets EMA Acceptance for Pain Management Drug Exparel
by Zacks Equity Research
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2%
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
by Zacks Equity Research
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Conatus' Emricasan Lags Primary Goal in Liver Function Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.
Alnylam Presents New Data for RNAi Therapeutic Onpattro
by Zacks Equity Research
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
Epizyme Announces Positive Interim Data on Lead Candidate
by Zacks Equity Research
Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
BioMarin Gets $15M From Pfizer on Talzenna's European Nod
by Zacks Equity Research
BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.
Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
by Zacks Equity Research
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Alexion's sBLA for Ultomiris Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
by Zacks Equity Research
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
by Zacks Equity Research
Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
by Zacks Equity Research
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
by Zacks Equity Research
Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.
Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
by Zacks Equity Research
Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.
Dr. Reddy's Inks Deal to Sell Neurology Branded Products
by Zacks Equity Research
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
by Zacks Equity Research
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Acorda Therapeutics Enters Oversold Territory
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.